ReviewCancer immunology, immunotherapy : CII2004
Tumour escape: antitumour effectors too much of a good thing?
Review in Cancer immunology, immunotherapy : CII, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 87 citations in OpenAlex.
- EZH2 inhibition: a promising strategy to prevent cancer immune editing.Epigenomics · 2020Review
- Stroma as an Active Player in the Development of the Tumor Microenvironment.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2015Article
- Association of HLA-B*51:01 with papillary thyroid carcinoma in the Chinese Han population of the Shandong coastal areas.Thyroid : official journal of the American Thyroid Association · 2014Article
- Molecular profiling predicts the existence of two functionally distinct classes of ovarian cancer stroma.BioMed research international · 2013Article
- DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?Genetic vaccines and therapy · 2012Article
- Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.Cancer immunology, immunotherapy : CII · 2012Article
- Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency.Clinical and experimental immunology · 2011Article
- Revisiting the seed and soil in cancer metastasis.The international journal of biochemistry & cell biology · 2009Review
- Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-cell response against pediatric nasopharyngeal carcinoma in vitro.Medical oncology (Northwood, London, England) · 2009Article
- Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics.Current pharmaceutical design · 2009Review
- Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.Cancer immunology, immunotherapy : CII · 2008Article
- HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
- Examination of oral cancer biomarkers by tissue microarray analysis.Archives of otolaryngology--head & neck surgery · 2008Article
- In vivo tumor secretion probing via ultrafiltration and tissue chamber: implication for anti-cancer drugs targeting secretome.Recent patents on anti-cancer drug discovery · 2008Review
- Prognostic significance of RCAS1 expression in relation to the infiltration of dendritic cells and lymphocytes in patients with esophageal carcinoma.Digestive diseases and sciences · 2007Article
- Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands.Cancer immunology, immunotherapy : CII · 2007Review
- Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma.Cancer immunology, immunotherapy : CII · 2007Review
- Tumor escape mechanisms in prostate cancer.Cancer immunology, immunotherapy : CII · 2007Review
- Tumor stroma-associated antigens for anti-cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2006Review
- Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.Cancer immunology, immunotherapy : CII · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although even "spontaneous" tumours are immunogenic and are commonly infiltrated by tumour antigen-specific T cells (at least in melanoma), most tumours are not completely rejected by the host, and cancer progresses. There is a growing realisation that many responses defined as antitumour effector mechanisms act as double-edged swords and under different conditions either become ineffective or even protumorigenic. Examples are interleukin 2 (also proapoptotic for activated T cells), interferon gamma (by induction of ligands for T and NK cell inhibitory receptors), angiogenesis inhibition (by hypoxia-mediated induction of growth factors promoting metastasis), and macrophage free radical-mediated cytotoxicity (by inhibiting T cells). Immune selection pressure itself, resulting in outgrowth of resistant tumour variants could also be viewed in this light. On the other hand, knowledge of the many tumour escape pathways offers the theoretical possibility of reconstituting antitumour immunity. Tumour escape from immunosurveillance represents the last series of hurdles to be overcome in formulating truly effective cancer immunotherapy, but given the immense plasticity of the tumour cell, and the complex balance between pro- and antitumour activity of the very same effector pathways, this remains a major challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.